Health Research Registry List

Research Registry No : HRID-00054_V21
 
University Departmental Research : Yes
 
Name of University : DMR
 
Department : Technology Development Division
 
Registration Date : 2020-05-15
 
Title of Research : Human Papillomavirus (HPV) DNA testing based Cervical Cancer Screening in Magway Region
 
Principle Investigator : Mu Mu Shwe
 
Co-authors : Khin May Thinn, Lei Lei Aye Thaung, Lynn Pa Pa Aye, Kham Mo Aung, May Zon Myint , Kyaw Soe Tun, Myat Soe, Win Maw Tun
 
Field of Research : Pathology
 
Publication Source :
 
 
Year of Publication : -
 
URL of Publication : -
 
Presentation Source : 66th Myanmar Medical Association, 2020 February
 
Placement of Presentation : MMA
 
Year of Presentation : 2020
 
Abstract : Background: Human Papillomavirus (HPV) is the primary cause of cervical cancer which is the first leading cause of female cancer in Myanmar. Therefore, screening women for the presence of HPV is a critical aspect for prevention and early treatment of cervical cancer. Objectives: The objectives were to conduct HPV-DNA-testing-based-Cervical Cancer Screening among married women in Magway Region and to identify the cervical abnormalities among women who have HPV-infection. Methods: It was a prospective cross-sectional descriptive study. Total of asymptotic 264 married women (median age-40-years; range 30-50) residing in Magway region were screened in 2019. Cervical cells were obtained by sterile-disposable-Carebrush and collected in Care-collection-media. HPV-DNA-testing was performed using CareHPV-Test which detects pooled-14-high-risk-HPV-16,-18,-31,-33,-35,-39,-45,-51,-52,-56,-58,-59,-66and-68. HPV-positive-cases were followed by colposcopy-directed-biopsy and histology and HPV16/18 genotyping using GeneXpertHPV-Test. .Results: HPV was identified in 6.1% of screened women in Magway region. Among HPV-positive-cases, other-HR-HPV-genotypes (HPV-31,-33,-35,-39,-51,-52,-56,-58,-59,-66and-68) were 75%, HPV-16 (12.5%) and HPV-18/45 (12.5%). Histologically, 43.8% had chronic cervicitis, 37.5% had cervical intraepithelial neoplasia (CIN)-1, 12.5% (CIN-2) and 6.2% (Carcinoma-in-situ). Among HPV infected chronic cervicitis cases, HPV-16 was 6.2%, HPV18/45 (12.5%) and other-HR-HPV-genotypes (25.0%). All HPV-positive CIN-1 and CIN-2 cases had other-HR-HPV-genotypes. All HPV-positive Carcinoma-in-situ cases had HPV-16. Conclusions: This study highlighted that using HPV-DNA test in cervical cancer screening, the most-highest risk women who may develop cervical cancer can be determined. Therefore, early detection and effective management can be performed. Using HPV-DNA test, refer to hospital for appropriate management and/or follow up and burden of health care providers for cervical cancer screening will be reduced.
 
 
IRB/PRC/ERC Approval Date : 2019-08-13
 
Placement of IRB/PRC/ERC : DMR
 
IRB/PRC/ERC Approval Letter/Document : 15052020061619IRB2019-74Magway.pdf
 
Pre-existing Registration ID : -
 
Pre-existing Name of Organization : -
 
Pre-existing Website : -